


CellMosaic, Inc. 10A Roessler Road Woburn, MA 01801, USA Phone: 781-463-0002; Fax: 781-998-4694; E-mail: info@cellmosaic.com

BSA-Deruxtecan Conjugate

Lyophilized powder, 1 mg per vial, ≥99% conjugates by SEC HPLC

Product Number: CM52140



Product Description

Deruxtecan is an exatecan (Exa) derivative, appended with a cleavable peptide linker, is a very potent inhibitor of topoisomerase I and anticancer agent. Deruxtecan is used to prepare antibody-drug conjugates, such as trastuzumab Deruxtecan (T-DXd, also known as Enhertu®, Daiichi Sankyo), targeting HER2 and is approved in HER2-expressing breast (BC) and gastric (GC) cancers. This BSA-Deruxtecan conjugate is designed with same linker chemistry as PDC prepared by our customer using CellMosaic's Protein Deruxtecan Conjugation Kit (Cat#: CM11432). The conjugate is synthesized at CellMosaic and has an average of 3 to 5 Deruxtecan molecules per BSA for immunization or immunoassay development. The final conjugate is lyophilized from PBS containing sugar-based stabilizer for easy shipping and storage.

The product is sold as either 1 vial of 1 mg (Cat# CM52140-1MG) or 5 vials of 1 mg (Cat# CM52140-5MG). For bulk orders, please contact us for a quote.

Application

- Assay development for detection of Deruxtecan or Deruxtecan metabolites in vitro or in vivo.
- Antibody discovery via immunization and hapten recognition
- Indirect and competitive ELISA assay

Key Features

- Lyophilized powder and ready for usage after reconstitution with water, no need for external buffer
- Optimized loading with an average 3 to 5 Deruxtecan molecules per BSA
- Amount accurately determined by UV/HPLC analysis.

Storage/Stability

- Recommended storage of the product is below -20°C
- Expiration before defrosting is 1 year after receiving.
- Once defrosted maintain at 2-8°C.
- For best quality use within 1 week of defrosting.

Selected References for Deruxtecan ADC

1) Takashi Nakada, et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. *Bioconjugic & Medicinal Chem. Lett.* **2016**;26: 1542–45.

2) Yusuke Ogitani, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. *Cancer Sci.* **2016**;107(7):1039–46.

3) Naoki Takegawa, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. *Int. J. Cancer.* **2017**;141:1682-89.